Harnessing therapeutic potential of novel Spisulosine derivative as robust autophagy inducer against Triple Negative Breast Cancer (TNBC) in-vitro & in-vivo | India Science, Technology & Innovation - ISTI Portal

×

Acces sibility Controls

Harnessing therapeutic potential of novel Spisulosine derivative as robust autophagy inducer against Triple Negative Breast Cancer (TNBC) in-vitro & in-vivo

Implementing Organization

CSIR-Central Drug Research Institute (CSIR-CDRI), Uttar Pradesh

Principal Investigator

Dr. D. Datta

CSIR-Central Drug Research Institute (CSIR-CDRI), Uttar Pradesh

Source

Source

Extramural R&D Projects listed in NSTMIS database 2019-20

Related Research

Quick Information

Area of Research

Medical Sciences

Focus Area

Ad-hoc, ADHOC

Start Year

2019

End Year

2022

Sanction Amount

₹ 16.60 L

Status

Completed

Output

No. of Research Paper

00

Technologies (If Any)

00

No. of PhD Produced

00

No. of Patents

Filed : 00

Grant : 00

Disclaimer: Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.

Latest Updates

Loading…